0001610717-23-000291.txt : 20230920 0001610717-23-000291.hdr.sgml : 20230920 20230920062308 ACCESSION NUMBER: 0001610717-23-000291 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230919 FILED AS OF DATE: 20230920 DATE AS OF CHANGE: 20230920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burow Kristina CENTRAL INDEX KEY: 0001569248 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41802 FILM NUMBER: 231265267 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neumora Therapeutics, Inc. CENTRAL INDEX KEY: 0001885522 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 844367680 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (857) 760-0900 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: RBNC Therapeutics, Inc. DATE OF NAME CHANGE: 20210929 4 1 form4.xml X0508 4 2023-09-19 0001885522 Neumora Therapeutics, Inc. NMRA 0001569248 Burow Kristina C/O NEUMORA THERAPEUTICS, INC. 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 true true false Common Stock 2023-09-19 4 C 0 13620 A 13620 D Common Stock 2023-09-19 4 C 0 684167 A 684167 I See Footnotes Common Stock 2023-09-19 4 C 0 1144973 A 1144973 I See Footnotes Common Stock 2023-09-19 4 C 0 6895021 A 12205379 I See Footnotes Common Stock 2023-09-19 4 C 0 6576400 A 11886758 I See Footnotes Common Stock 2023-09-19 4 C 0 2124143 A 2124143 I See Footnote Common Stock 2023-09-19 4 P 0 1500000 17 A 3624143 I See Footnote Series A-1 Preferred Stock 2023-09-19 4 C 0 13620 D Common Stock 13620 0 D Series A-1 Preferred Stock 2023-09-19 4 C 0 684167 D Common Stock 684167 0 I See Footnotes Series A-1 Preferred Stock 2023-09-19 4 C 0 1144973 D Common Stock 1144973 0 I See Footnotes Series A-2 Preferred Stock 2023-09-19 4 C 0 6895021 D Common Stock 6895021 0 I See Footnotes Series A-2 Preferred Stock 2023-09-19 4 C 0 6576400 D Common Stock 6576400 0 I See Footnotes Series B Preferred Stock 2023-09-19 4 C 0 2124143 D Common Stock 2124143 0 I See Footnote The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. AVP VII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VII LLC and owns an interest in AVP VII LP but does not have voting or investment control over the shares held by ARCH VII. Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. AVP VIII LLC Managing Directors each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The Reporting Person is a managing director at AVP VIII LLC and owns an interest in AVP VIII LLC but does not have voting or investment control over the shares held by ARCH VIII Overage. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. AVP XII LLC Committee Members each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. /s/ Joshua Pinto, as Attorney-in-Fact for Kristina M. Burow 2023-09-19